A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy-Reference-Cited by-同舟云学术

A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy

Published:2015-01 Issue:1 Volume:23 Page:192-201
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Mendell Jerry R,Sahenk Zarife,Malik Vinod,Gomez Ana M,Flanigan Kevin M,Lowes Linda P,Alfano Lindsay N,Berry Katherine,Meadows Eric,Lewis Sarah,Braun Lyndsey,Shontz Kim,Rouhana Maria,Clark Kelly Reed,Rosales Xiomara Q,Al-Zaidy Samiah,Govoni Alessandra,Rodino-Klapac Louise R,Hogan Mark J,Kaspar Brian K

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference63 articles.

1. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin;England;Nature,1990

2. 42nd ENMC Sponsored International Workshop: X-linked cardiomyopathies. 21-23 June 1996, Naarden, The Netherlands;Nigro;Neuromuscul Disord,1997

3. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities;Bushby;J Neurol,1993

4. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies;Beggs;Am J Hum Genet,1991

5. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations;Aartsma-Rus;Hum Mutat,2009

Cited by 193 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles;Cell;2024-09

2. Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients;International Journal of Molecular Sciences;2024-08-12

3. Dual FKRP/FST gene therapy normalizes ambulation, increases strength, decreases pathology, and amplifies gene expression in LGMDR9 mice;Molecular Therapy;2024-08

4. Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy;Neurology International;2024-07-05

5. Systemic Treatment of Body‐Wide Duchenne Muscular Dystrophy Symptoms;Clinical Pharmacology & Therapeutics;2024-07-04